These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 29914292)
41. The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions. Siegel SD; Lerman C; Flitter A; Schnoll RA Cancer Prev Res (Phila); 2020 Mar; 13(3):261-272. PubMed ID: 32132120 [TBL] [Abstract][Full Text] [Related]
42. A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. Weiss RB; Baker TB; Cannon DS; von Niederhausern A; Dunn DM; Matsunami N; Singh NA; Baird L; Coon H; McMahon WM; Piper ME; Fiore MC; Scholand MB; Connett JE; Kanner RE; Gahring LC; Rogers SW; Hoidal JR; Leppert MF PLoS Genet; 2008 Jul; 4(7):e1000125. PubMed ID: 18618000 [TBL] [Abstract][Full Text] [Related]
43. Genetics and smoking cessation improving outcomes in smokers at risk. Lerman CE; Schnoll RA; Munafò MR Am J Prev Med; 2007 Dec; 33(6 Suppl):S398-405. PubMed ID: 18021915 [TBL] [Abstract][Full Text] [Related]
44. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Hutchison KE; Allen DL; Filbey FM; Jepson C; Lerman C; Benowitz NL; Stitzel J; Bryan A; McGeary J; Haughey HM Arch Gen Psychiatry; 2007 Sep; 64(9):1078-86. PubMed ID: 17768273 [TBL] [Abstract][Full Text] [Related]
45. Intermediacy and gene-environment interaction: the example of CHRNA5-A3 region, smoking, nicotine dependence, and lung cancer. Wacholder S; Chatterjee N; Caporaso N J Natl Cancer Inst; 2008 Nov; 100(21):1488-91. PubMed ID: 18957674 [No Abstract] [Full Text] [Related]
46. Associations of variants in CHRNA5/A3/B4 gene cluster with smoking behaviors in a Korean population. Li MD; Yoon D; Lee JY; Han BG; Niu T; Payne TJ; Ma JZ; Park T PLoS One; 2010 Aug; 5(8):e12183. PubMed ID: 20808433 [TBL] [Abstract][Full Text] [Related]
47. [Pharmacogenetics in the treatment of tobacco addiction]. Quaak M; van Schooten FJ; van Schayck CP Tijdschr Psychiatr; 2013; 55(11):891-8. PubMed ID: 24242150 [TBL] [Abstract][Full Text] [Related]
48. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Benowitz NL Clin Pharmacol Ther; 2008 Apr; 83(4):531-41. PubMed ID: 18305452 [TBL] [Abstract][Full Text] [Related]
49. Role of nicotine dependence on the relationship between variants in the nicotinic receptor genes and risk of lung adenocarcinoma. Tseng TS; Park JY; Zabaleta J; Moody-Thomas S; Sothern MS; Chen T; Evans DE; Lin HY PLoS One; 2014; 9(9):e107268. PubMed ID: 25233467 [TBL] [Abstract][Full Text] [Related]
50. [Association between genotype and allele frequencies of CYP2A6*12 and rs16969968 in CHRNA5 variants with smoking and body mass index in young subjects from Northeast Mexico]. Borrego-Soto G; Costilla-Esquivel A; Padilla-Rivas GR; Cázares-Samaniego PJ; Posadas-Valay R; Velasco-Castañón JG; Mercado-Longoria R; Ortiz-López R; Rojas-Martínez A Rev Med Chil; 2015 Nov; 143(11):1377-85. PubMed ID: 26757861 [TBL] [Abstract][Full Text] [Related]
51. Association Between Nicotine-dependent Gene Polymorphism and Smoking Cessation in Patients With Lung Cancer. Gu F; Zhao C; Jiang T; Li X; Mao Y; Zhou C Clin Lung Cancer; 2020 Mar; 21(2):171-176. PubMed ID: 31402126 [TBL] [Abstract][Full Text] [Related]
52. Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. Chen LS; Baker TB; Jorenby D; Piper M; Saccone N; Johnson E; Breslau N; Hatsukami D; Carney RM; Bierut LJ Drug Alcohol Depend; 2015 Sep; 154():278-82. PubMed ID: 26142345 [TBL] [Abstract][Full Text] [Related]
55. Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers. Falcone M; Jepson C; Benowitz N; Bergen AW; Pinto A; Wileyto EP; Baldwin D; Tyndale RF; Lerman C; Ray R Nicotine Tob Res; 2011 Jun; 13(6):498-503. PubMed ID: 21385908 [TBL] [Abstract][Full Text] [Related]
56. Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. Janes AC; Smoller JW; David SP; Frederick BD; Haddad S; Basu A; Fava M; Evins AE; Kaufman MJ Drug Alcohol Depend; 2012 Jan; 120(1-3):7-13. PubMed ID: 21764527 [TBL] [Abstract][Full Text] [Related]
57. Contribution of Variants in CHRNA5/A3/B4 Gene Cluster on Chromosome 15 to Tobacco Smoking: From Genetic Association to Mechanism. Wen L; Jiang K; Yuan W; Cui W; Li MD Mol Neurobiol; 2016 Jan; 53(1):472-484. PubMed ID: 25471942 [TBL] [Abstract][Full Text] [Related]
58. Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Baker TB; Weiss RB; Bolt D; von Niederhausern A; Fiore MC; Dunn DM; Piper ME; Matsunami N; Smith SS; Coon H; McMahon WM; Scholand MB; Singh N; Hoidal JR; Kim SY; Leppert MF; Cannon DS Nicotine Tob Res; 2009 Jul; 11(7):785-96. PubMed ID: 19436041 [TBL] [Abstract][Full Text] [Related]
59. The science of tobacco addiction and cessation. Cancer Discov; 2014 Jan; 4(1):12-3. PubMed ID: 24402931 [TBL] [Abstract][Full Text] [Related]
60. Identification of pharmacogenetic markers in smoking cessation therapy. Heitjan DF; Guo M; Ray R; Wileyto EP; Epstein LH; Lerman C Am J Med Genet B Neuropsychiatr Genet; 2008 Sep; 147B(6):712-9. PubMed ID: 18165968 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]